Company intelligence / Profile preview

Endovision

Hong Kong, Hong Kong

Ownership: Private
Employees: ~26
Development stage: Other

Overview

Endovision develops AI-powered software to enhance the diagnostic accuracy and procedural quality of upper gastrointestinal endoscopy. Its flagship product, Cerebro, has received EU MDR certification. The company’s technology leverages deep learning to assist clinicians with real-time decision support during endoscopic procedures, aiming to improve outcomes and standardize care.

Therapeutic areas: GastroenterologyOncology
Modalities: DeviceSoftware (AI-based medical device)
Industry: Medical Imaging

Partnerships

Cosmo Pharmaceuticals N.V.

Beyond the preview

Go deeper on Endovision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endovision.

Explore the full profile